(HealthDay News) — The ChemPro 100-electronic nose can discriminate prostate cancer from benign prostatic hyperplasia using urine headspace, according to a study published in The Journal of Urology.

Antti Roine, MD, from the University of Tampere in Finland, and colleagues investigated the ability of an electronic nose (ChemPro 100-eNose) to discriminate prostate cancer from benign prostatic hyperplasia using urine sample headspace. 

RELATED: Surgery May Improve Survival in Younger Prostate Cancer Patients


Continue Reading

Performance was tested with samples from 50 patients with confirmed prostate cancer scheduled to undergo robotic assisted laparoscopic radical prostatectomy and 24 samples from 15 patients with benign prostatic hyperplasia scheduled to undergo transurethral resection of the prostate. Urine samples were provided preoperatively, and those with benign prostatic hyperplasia also provided samples postoperatively to be used as a pooled control population.

The researchers found that the eNose reached a sensitivity of 78% and a specificity of 67% using leave-one-out cross-validation. The area under the receiver operating characteristic curve was 0.77.

“The electronic nose is capable of rapidly and noninvasively discriminating prostate cancer and benign prostatic hyperplasia using urine headspace in patients undergoing surgery,” the researchers wrote.

One author disclosed financial ties to Amgen, Astellas, Sanofi-Aventis, and Bayer.

Reference

  1. Roine A, Veskimäe E, Tuokko A, et al. Detection of Prostate Cancer by an Electronic Nose: A Proof of Principle Study. J Urol. 2014;doi:10.1016/j.juro.2014.01.113.